Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all

gan Grebely, J., Litwin, A., Dore, G. J.
Cyhoeddwyd yn J Viral Hepat (2016)

A239 QUALITATIVE EVALUATION OF THE DECISIONS AND EXPERIENCES OF PEOPLE WHO INJECT DRUGS WHO RECEIVED A LIVER DISEASE ASSESSMENT AS PART OF A LIVER HEALTH PROMOTION CAMPAIGN: THE LI...

gan Marshall, A D, Treloar, C, Dore, G J, Grebely, J
Cyhoeddwyd yn J Can Assoc Gastroenterol (2018)

A165 SHORT INJECTION CESSATION EPISODES AS OPPORTUNITIES FOR HEPATITIS C PREVENTION

gan Fortier, E, Artenie, A, Jutras-Aswad, D, Roy, É, Grebely, J, Bruneau, J
Cyhoeddwyd yn J Can Assoc Gastroenterol (2018)

Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study

gan Grebely, J, Petoumenos, K, Matthews, GV, Haber, P, Marks, P, Lloyd, AR, Kaldor, JM, Dore, GJ, Hellard, M
Cyhoeddwyd 2010

P232 MOLECULAR PHYLOGENETICS OF HEPATITIS C VIRUS (HCV) AS A TOOL TO UNDERSTAND THE HCV EPIDEMIC IN BRITISH COLUMBIA (BC), CANADA

gan Olmstead, A., Krajden, M., Montoya, V., Grebely, J., Poon, A.F.Y., Harrigan, P.R., Joy, J.B.
Cyhoeddwyd yn J Hepatol (2014)

A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs

gan Spelman, T, Morris, MD, Zang, G, Rice, T, Page, K, Maher, L, Lloyd, A, Grebely, J, Dore, GJ, Kim, AY, Shoukry, NH, Hellard, M, Bruneau, J
Cyhoeddwyd yn J Epidemiol Community Health (2015)

A161 ONGOING INCIDENT HEPATITIC C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING

gan Cunningham, E B, Hajarizadeh, B, Amin, J, Betz-Stablein, B, Dore, G J, Luciani, F, Teutsch, S, Bretana, N A, Dolan, K, Lloyd, A R, Grebely, J
Cyhoeddwyd yn J Can Assoc Gastroenterol (2018)

Patterns and Characteristics of Hepatitis C Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C

gan Matthews, G. V., Pham, S. T., Hellard, M., Grebely, J., Zhang, L., Oon, A., Marks, P., van Beek, I., Rawlinson, W., Kaldor, J. M., Lloyd, A., Dore, G. J., White, P. A.
Cyhoeddwyd 2011

Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection

gan Dore, GJ, Hellard, M, Matthews, G, Grebely, J, Haber, PS, Petoumenos, K, Yeung, B, Marks, P, van Beek, I, McCaughan, G, White, P, Ffrench, R, Rawlinson, W, Lloyd, AR, Kaldor, JM
Cyhoeddwyd 2009

Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada

gan Jacka, B, Applegate, T, Krajden, M, Olmstead, A, Harrigan, PR, Marshall, BDL, DeBeck, K, Milloy, M-J, Lamoury, F, Pybus, OG, Lima, VD, Magiorkinis, G, Montoya, V, Montaner, J, Joy, J, Woods, C, Dobrer, S, Dore, GJ, Poon, AF, Grebely, J
Cyhoeddwyd 2014

A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (...

gan Conway, B, Dore, G J, Altice, F, Litwin, A, Grebely, J, Dalgard, O, Gane, E J, Shibolet, O, Luetkemeyer, A, Nahass, R, Peng, C, Gendrano, I, Huang, H, Chen, E, Nguyen, B, Wahl, J, Barr, E, Robertson, M, Platt, H
Cyhoeddwyd yn J Can Assoc Gastroenterol (2018)